
FACT resumes caprolactam production
The Hindu
Move likely to add ₹700 crore to company’s turnover
Fertilizers and Chemicals Travancore has restarted production of caprolactam after a gap of nearly nine years years, making it a "momentous" event for the public sector company. While restarting caprolactam will add about ₹600 crore to ₹700 crore to the turnover of the company, the product from FACT will also be a major import substitution. The restarting of caprolactam production comes as the country is celebrating “Azadi Ka Amrith Mahotsav” in line with the nation’s vision of achieving self-sufficiency, said a communication from FACT here. FACT has a capacity to produce 50,000 tonnes of caprolactam per year. Caprolactam is produced in India by FACT and Gujarat State Fertilizer Company. There is a demand for 1.2 lakh tonnes to 1.3 lakh tonnes of caprolactam in the country annually and FACT expects to sell most of its product in the domestic market, considering the quality of the product and reputation enjoyed by the company.
‘Instead of accusing Gen-Z of lacking skills or discipline, we need to ask what drives them’ Premium
At a recent event held in the city, Cambridge University Press & Assessment launched an advisory panel comprising leaders from top global corporations, aiming to bridge the employability gap in India and better align academic output with industry needs. A whitepaper released at the event highlighted the growing importance of communication skills, the need for stronger collaboration between industry and universities, and strategies to bridge the persistent skill gap.

Under the NBS, newborns are screened for communication disorders before they are discharged from the hospital. For this, AIISH has collaborated with several hospitals to conduct screening which is performed to detect hearing impairment and other developmental disabilities that can affect speech and language development. The screening has been helping in early intervention for those identified with the disorders, as any delay in the identification poses risk and affects successful management of children with hearing loss, according to AIISH.